Renal tissue regeneration

Patent metadata

Field	Value
Publication number	US-9694055-B2
Application number	US-99181109-A
Country	US
Kind code	B2
Filing date	May 11, 2009
Priority date	May 9, 2008
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue.

First claim

The invention claimed is:

1. A method of inducing renal progenitor cell recruitment to the kidney parenchyma of a subject comprising: obtaining a substantially cell-free biocompatible collagen thermogel that will thermogel as it reaches body temperature and maintain a viscosity greater than water for more than 1 hour when gelled; chilling the substantially cell-free biocompatible collagen thermogel below its gelation temperature; injecting the chilled, substantially cell-free biocompatible collagen thermogel into the kidney parenchyma of the subject with an injection needle; measuring the pressure in the kidney parenchyma during injection with a pressure sensor; continuing injection of the chilled, substantially cell-free biocompatible collagen thermogel until a positive pressure in a range from about 5 cmH20 to about 20 cmH20 in the kidney parenchyma is obtained by the injecting step; maintaining the positive pressure for at least one hour after injection due to gelation of the substantially cell-free biocompatible collagen thermogel as it reaches body temperature; and creating a hyperbaric environment caused by the step of injecting the substantially cell-free biocompatible collagen thermogel into the kidney parenchyma, whereby renal progenitor cells are recruited to the kidney parenchyma.

2. The method of claim 1 , wherein the biocompatible collagen thermogel is a solution having a collagen concentration from about 1 mg/mL to about 30 mg/mL.

3. The method of claim 1 , wherein the viscosity of the biocompatible collagen thermogel is between about 5 cP to about 1×10 8 cP at 25° C.

4. A method of kidney regeneration comprising: obtaining a substantially cell-free biocompatible collagen thermogel that will thermogel as it reaches body temperature and maintain a viscosity greater than water for more than 1 hour when gelled; chilling the substantially cell-free biocompatible collagen thermogel below its gelation temperature; injecting the chilled, substantially cell-free biocompatible collagen thermogel into the kidney parenchyma of a subject with an injection needle; measuring the pressure in the kidney parenchyma during injection with a pressure sensor; continuing injection of the chilled substantially cell-free biocompatible collagen thermogel at the kidney parenchyma until a positive pressure in a range from about 5 cmH20 to about 20 cmH20 is obtained by the injecting step; creating a hyperbaric environment in the kidney parenchyma caused by the step of injecting the substantially cell-free biocompatible collagen thermogel; and maintaining the positive pressure in the kidney parenchyma for at least one hour due to gelation of the substantially cell-free biocompatible collagen thermogel as it reaches body temperature, whereby renal progenitor cells are recruited to the kidney parenchyma and differentiate into new glomeruli structures within the kidney parenchyma one week after the step of injection.

5. A method of inducing in situ renal tissue regeneration in the kidney parenchyma of a subject comprising: obtaining a substantially cell-free biocompatible collagen thermogel that will thermogel as it reaches body temperature and maintain a viscosity greater than water for more than 1 hour when gelled; chilling the substantially cell-free biocompatible collagen thermogel below its gelation temperature; injecting the chilled substantially cell-free biocompatible collagen thermogel and at least one adjuvant into the kidney parenchyma of the subject with an injection needle; measuring the pressure during injection with a pressure sensor; continuing injection of the chilled substantially cell-free biocompatible collagen thermogel and adjuvant until a positive pressure in a range from about 5 cmH20 to about 20 cmH20 is obtained by the injecting step; maintaining the positive pressure in the kidney parenchyma for a period of time due to gelation of the substantially cell-free biocompatible collagen thermogel as it reaches body temperature, whereby renal progenitor cells are recruited to the kidney parenchyma and differentiate into renal tissue one week after the step of injection.

6. The method of claim 5 , wherein the adjuvant is incorporated into the biocompatible collagen thermogel.

7. The method of claim 5 , wherein the adjuvant comprises an anti-inflammatory agent comprising dexamethasone.

8. The method of claim 7 , wherein the anti-inflammatory agent comprises a collagen synthetase inhibitor.

9. The method according to claim 1 , further comprising performing the method of claim 1 multiple times over a period of time.

10. The method according to claim 4 , further comprising performing the method of claim 4 multiple times over a period of time.

11. The method according to claim 5 , further comprising performing the method of claim 5 multiple times over a period of time.

Assignees

• Yoo James
• Lee Sang Jin
• Van Dyke Mark
• Atala Anthony
• Univ Wake Forest Health Sciences

Inventors

• Yoo James
• Lee Sang Jin
• Van Dyke Mark
• Atala Anthony

Classifications

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61L27/24

  Collagen · CPC title

• A61L27/52

  Hydrogels or hydrocolloids · CPC title

• A61L2300/41

  Anti-inflammatory agents, e.g. NSAIDs · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title